Biogen Inc. (ETR:IDP)
Germany
· Delayed Price · Currency is EUR | Market Cap | 16.39B |
| Revenue (ttm) | 9.08B |
| Net Income (ttm) | 1.37B |
| Shares Out | n/a |
| EPS (ttm) | 9.36 |
| PE Ratio | 11.98 |
| Forward PE | 8.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 234 |
| Average Volume | 293 |
| Open | 112.35 |
| Previous Close | 111.00 |
| Day's Range | 109.40 - 112.35 |
| 52-Week Range | 99.00 - 220.00 |
| Beta | 0.12 |
| RSI | 42.29 |
| Earnings Date | May 1, 2025 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal
Paris, May 12 , 2025 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien E...
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) on Thursday reported a first-quarter 2025 adjusted EPS loss of 1 cent, beating the consensus loss of $(1.03) . The company reported quarterly sales of $594....
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact
Biogen Inc. (NASDAQ: BIIB) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’s down from $3.67 a year ago, beating the analyst consensus of $2.52 . The c...
Biogen outlines growth strategy with LEQEMBI and SKYCLARYS advancements for 2025
Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript
BIIB Earnings: Biogen Q1 2025 adj. profit drops despite higher revenues
Biotechnology firm Biogen Inc. (NASDAQ: BIIB) Thursday reported a year-over-year decrease in adjusted profit for the first quarter of 2025, despite an increase in revenues. Total revenue rose 6% year-...
Biogen Inc. 2025 Q1 - Results - Earnings Call Presentation
Earnings Snapshot: Biogen FY profit outlook misses estimates even as Q1 beats
Biogen Non-GAAP EPS of $3.02, revenue of $2.43B
Biogen beats quarterly profit estimates on strong demand for rare disease drugs
Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis drugs.
Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar
Biogen stock could pop Thursday after the biotech company beat first-quarter expectations, including strong sales for two newcomer drugs.
Biogen Q1 2025 Earnings Preview
Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?
Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion
The European Commission (EC) on Tuesday approved Eisai Co., Ltd. (OTC: ESALY) and Biogen Inc.’s (NASDAQ: BIIB) amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) , The Commission said it gran...
Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) wh...
Biogen/ Eisai win EU approval for Alzheimer’s therapy
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease
The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat mild cognitive impairment in the early stages of Alzheimer's disease.
Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Several exemptions exist among President Donald Trump ‘s broad tariffs , which were announced on Wednesday . The biopharma industry has historically been shielded from tariffs, including during Trump’...
Biogen downgraded to Hold at Argus on profit decline expectations
Biogen’s tau targeting Alzheimer’s disease therapy gets FDA Fast Track status
Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an inves...
Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.
Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment Organon (NYSE: OGN), a global healthcare company with a deep expertise in biosimilars, today an...
European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen
European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued an opinion that does not recommend Eli Lilly and Co's (NYSE: LLY) donanemab be granted marketing authori...